FDA Granted Hopstem’s hNPC01 for Chronic Ischemic Stroke Approval to Enter Phase 2/3 Adaptive Pivotal Clinical Trial with Bridging Study

The approval of this accelerated pathway not only demonstrates the FDA’s full recognition of the quality, safety, and efficacy of the Phase 1 clinical data of hNPC01 in China, but also will ...
PharmaTimes

Cellistic launches new iPSC-based platforms to expand immuno-oncology therapies

Cellistic has unveiled three new GMP manufacturing platforms designed to advance iPSC-derived cell therapies across ...

Japanese researchers confirm efficacy of iPS cell-based cancer treatment

A group of researchers in Japan says it has confirmed a certain level of efficacy in using iPS cell-derived immune cells for ...
Business Wire

bit.bio to Unveil iPSC Advancements and ioCells Toolkit at Society for Neuroscience 2024 Annual Conference

bit.bio's ioSensory Neurons pain research was selected for presentation at SfN’s Neuroscience 2024 press conference, and it was chosen from over 10,500+ submissions. bit.bio will host an expert panel ...
Morningstar

iPSC-CAR-NK Cell Therapy Clinical Result Published in Cell, Marking a Global Breakthrough in Autoimmune Disease Treatment

Hangzhou Qihan Biotech Co., Ltd. (“Qihan” or “Qihan Biotech” or “the Company”), an industry leader in applying multiplexable genome editing technology to cell therapies and organ transplantation, ...

TheWell Bioscience Unveils RocketCell(TM) 3D iPSC Xeno-Free Complete Growth Kit: A Comprehensive Xeno-Free Ecosystem for Scalable iPSC Expansion

Alongside the complete kit, TheWell Bioscience has released the RocketCell (TM) iPSC Xeno-Free Growth Medium. Available as a standalone product, this xeno-free medium is designed for researchers who ...
Nasdaq

Fate Therapeutics to Present Clinical and Preclinical Data on Off-the-Shelf iPSC-Derived Cell Therapies at EULAR 2025

Fate Therapeutics' off-the-shelf cell therapy product platform, including FT819, is gaining significant exposure by being selected for an oral presentation at the prominent EULAR 2025 congress. The ...
eLife

Patient-specific iPSC models of neural tube defects identify underlying deficiencies in neuroepithelial cell shape regulation and differentiation

Spina bifida and anencephaly are neural tube defects caused by failure of embryonic neural tube closure. Successful closure requires apicobasal elongation and apical constriction of neuroepithelial ...
Morningstar

Tolerance Bio’s Implanted iPSC-derived Thymic Organoids Enable In Vivo Positive Selection of Human T cells and Tumor Burden Reduction in Melanoma

Tolerance Bio’s Implanted iPSC-derived Thymic Organoids Enable In Vivo Positive Selection of Human T cells and Tumor Burden Reduction in Melanoma Patient-specific human immune system-bearing mouse ...
American Association of Individual Investors

Why Century Therapeutics, Inc.’s (IPSC) Stock Is Up 30.65%

As of Thursday, January 08, Century Therapeutics, Inc.’s IPSC share price has surged by 30.65%, which has investors ...

TheWell Bioscience Unveils RocketCell™ 3D iPSC Xeno-Free Complete Growth Kit: A Comprehensive Xeno-Free Ecosystem for Scalable iPSC Expansion

TheWell Bioscience is proud to announce the commercial launch of its new RocketCell™ product line, introducing two cutting-edge solutions for stem cell research: the RocketCell™ 3D iPSC Xeno-Free ...